Sarepta Therapeutics (SRPT) Tops Q3 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments
November 7, 2019 4:07 PM ESTCAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2019.
EXONDYS 51® (eteplirsen) enjoyed another strong quarter, with third quarter 2019 revenues of $99.0 million, a 26% increase over the same quarter in 2018.  Based on current performance, we have raised our full-year 2019 guidance from a range of $365 to $375 million to $370 to $380 million, stated Doug Ingram, Sareptas President and CEO.
Mr. Ingram continued, We have also made significant progress advancing... More
